Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.69 |
| ▸ | GAK | O14976 | 3/20 | 0.69 |
| ▸ | FBP1 | P09467 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.64 |
| ▸ | BUB1 | O43683 | 2/20 | 0.64 |
| ▸ | STK10 | O94804 | 2/20 | 0.64 |
| ▸ | MAP3K1 | Q13233 | 2/20 | 0.64 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.64 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.64 |
| ▸ | CARS1 | P49589 | 1/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.62 |
| ▸ | AURKA | O14965 | 2/20 | 0.62 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.62 |
| ▸ | PLK4 | O00444 | 1/20 | 0.62 |
| ▸ | CIT | O14578 | 1/20 | 0.62 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.62 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.62 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3873473 | 0.99 | EGFR (0.67) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL2607974 | 0.90 | EGFR (0.67) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL13285584 | 0.87 | EGFR (0.83) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL644810 | 0.87 | EGFR (0.83) | EGFRGAKFBP1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL28286584 | 0.86 | EGFR (0.82) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL642044 | 0.86 | EGFR (0.69) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL28814010 | 0.85 | EGFR (0.58) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL8684181 | 0.85 | EGFR (0.77) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL8684647 | 0.85 | EGFR (0.77) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL4356364 | 0.85 | EGFR (0.69) | EGFRGAKFBP1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS | Cellix Bio Provate Limited (IN) | 2022-05-26 | — | — | US | disclosed |
| US-11225464-B2 | Compositions and methods for the treatment of gastrointestinal polyps | CELLIX BIO PRIVATE LIMITED (IN) | 2022-01-18 | — | — | US | disclosed |
| US-20200190040-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS | CELLIX BIO PRIVATE LIMITED (IN) | 2020-06-18 | — | — | US | disclosed |
| WO-2018087605-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS | CELLIX BIO PRIVATE LIMITED (IN) | 2018-05-17 | — | — | WO | disclosed |
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| EP-3012251-B1 | PROCESS FOR THE PREPARATION OF 6,7-DIALKOXY QUINAZOLINE DERIVATIVES | NATCO PHARMA LTD (IN) | 2017-08-30 | — | — | EP | disclosed |
| EP-3015460-B1 | PROCESS FOR THE PREPARATION OF ERLOTINIB | CERBIOS-PHARMA S A (CH) | 2017-05-17 | — | — | EP | disclosed |
| US-20170079983-A1 | 6,7-DIALKOXY QUINAZOLINE DERIVATIVES AND METHODS OF TREATING DRUG RESISTANT AND OTHER TUMORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2017-03-23 | — | — | US | disclosed |
| US-20090306377-A1 | NOVEL PROCESS FOR THE PREPARTION OF ERLOTINIB | NATCO PHARMA LIMITED (IN) | 2009-12-10 | — | — | US | disclosed |
| US-20090306377-A1 | NOVEL PROCESS FOR THE PREPARTION OF ERLOTINIB | NATCO PHARMA LIMITED (IN) | 2009-12-10 | — | — | US | disclosed |
| WO-2008102369-A1 | NOVEL POLYMORPHS OF ERLOTINIB HYDROCHLORIDE AND METHOD OF PREPARATION | NATCO PHARMA LIMITED (IN) | 2008-08-28 | — | — | WO | disclosed |
| US-20080166358-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080166358-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080166358-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS INC. (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008076949-A2 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076949-A2 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007060691-A2 | A NOVEL PROCESS FOR THE PREPARATION OF ERLOTINIB | NATCO PHARMA LIMITED (IN) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007060691-A2 | A NOVEL PROCESS FOR THE PREPARATION OF ERLOTINIB | NATCO PHARMA LIMITED (IN) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | EGFR, ERBB2, ERBB4 | EGFR 1/4885GAK 900/4885FBP1 213/4885 |
| US-11225464-B2 | Compositions and methods for the treatment of gastrointestinal polyps | APC, LPXN, SCNN1G | EGFR 2217/4885GAK 2650/4885FBP1 1846/4885 |
| US-20090306377-A1 | NOVEL PROCESS FOR THE PREPARTION OF ERLOTINIB | ERBB4, ABL1, KRAS | EGFR 4/4885GAK 889/4885FBP1 2558/4885 |
| US-20200190040-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS | APC, LPXN, SCNN1G | EGFR 2217/4885GAK 2650/4885FBP1 1846/4885 |
| US-20220162171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS | APC, LPXN, SCNN1G | EGFR 2217/4885GAK 2650/4885FBP1 1846/4885 |
| US-20080166358-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | ABL1, FLT3, GRK5 | EGFR 19/4885GAK 892/4885FBP1 3745/4885 |
| US-20170079983-A1 | 6,7-DIALKOXY QUINAZOLINE DERIVATIVES AND METHODS OF TREATING DRUG RESISTANT AND OTHER TUMORS | ERBB2, EGFR, STK17A | EGFR 2/4885GAK 274/4885FBP1 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.